CLINICAL_TRIALS
trial_result
· 2014-07-16
Clinical Trial Update: Trial of TG4023 Combined With Flucytosine in Liver Tumors [Phase 1]
Summary
A Phase 1 study evaluating TG4023 in combination with flucytosine for hepatocellular carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Transgene | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED